In early B and T cells, variable domains of antigen receptors are somatically rearranged from V, D, and J gene loci by V(D)J recombination (1, 2). The lymphoid-specific factors recombination-activating gene 1 (Rag1) and Rag2 initiate V(D)J recombination by introducing a DNA double-strand break (DSB) at the junction between V, D, or J coding sequences and recombination signal sequences. DNA DSBs are then resolved by the nonhomologous end joining (NHEJ) DNA repair machinery, which is the main pathway for DNA DSB repair in mammalian cells. The following seven NHEJ factors have been identified so far: the heterodimer Ku70/Ku80, which forms the DNA–PK complex with the catalytic subunit of the DNA-dependent rotein kinase, Artemis, Cernunnos/XLF, XRCC4 (X4), and DNA ligase IV. The recently identified Cernunnos/XLF factor, whose precise function is not known, is part of the X4–DNA ligase IV complex (3–5). Mutations in genes coding for Artemis, DNA ligase IV, and Cernunnos (3, 6–8) are responsible for human radiosensitive severe combined immunodeficiency.

Likewise, gene inactivation of NHEJ factors in mice results in the absence of mature T and B lymphocytes and embryonic lethality in the case of X4 and DNA ligase IV (9–14). Upon antigen recognition in secondary lymphoid organs, IgM-expressing mature B cells further diversify their repertoire through class switch recombination (CSR), which exchanges the IgM constant region (Cμ) with a downstream CH gene (γ, ε, or α), producing antibodies with a different effector function (15). CSR involves large repetitive switch (S) region sequences located upstream of each CH gene, except for Cδ. Breaks are introduced in the DNA flanking the two participating S regions, followed by their fusion, while the intervening sequence, including Cμ, is excised. CSR requires transcription through the target regions, and is initiated by the activation-induced cytidine deaminase (AID) (16, 17). Several lines of evidence suggest that CSR, like V(D)J recombination, involves the generation of DNA DSB, and could potentially involve NHEJ factors for DNA DSB repair: (a) an episomal circle is generated during CSR (15); (b) DNA DSBS have been detected by ligated mediated PCR (LM-PCR) assays in the...
Sy3 region in mitogen-activated B cells (18); (c) foci of the phosphorylated histone H2AX (γH2AX), which form around DNA DSBs, occur at the IgH locus in an AID-dependent manner in B cells activated for CSR (19); and (d) CSR is impaired in mice deficient for H2AX, ATM, p53-binding protein 1 (53BP1) and Nbs1, which are early components of the DNA DSB response (20–26).

CSR cannot be directly analyzed in mice deficient in NHEJ factors, as these mice lack a mature immune system. A monoclonal mature B cell compartment has been reconstituted by introducing rearranged IgH and IgL chain knock-in alleles (HL mice) in mice deficient for NHEJ factors, except for X4 and DNA ligase IV, which are embryonic lethal. Ku70 and Ku80-deficient B cells have severely impaired CSR (20, 27, 28). Although this defect could result from a reduced proliferative capacity or an increased apoptosis when induced to undergo CSR (20, 27), Ku mutant Bcl-2 transgenic B cells that divide still do not undergo CSR (20). Conflicting results were reported concerning the role of DNA-PKcs in CSR (29–32). Finally, Artemis deficiency doesn’t have any impact on CSR in such monoclonal B cell mice (33). Although some key NHEJ components seem to be required for CSR, one cannot exclude a role outside of NHEJ per se for these factors. X4 and DNA ligase IV are the only factors without a known function apart from NHEJ. Recently, Pan-Hammerström et al. showed that B cells from patients with hypomorphic DNA ligase IV mutations display an altered pattern of junctional resolution, with increased microhomology in Sμjunctions (34), suggesting a possible implication of the X4–DNA ligase IV complex during CSR in humans.

We developed a conditional X4 KO mouse model. We show that specific inactivation of X4 in mature B cells results in a partial defect in CSR in vivo and in vitro, revealing the possible usage of an alternative pathway in the absence of XRCC4.

### RESULTS

#### Generation of lentiviral transgenic mice expressing mouse X4

X4-deficient mice are embryonic lethal at the embryonic day (E) 16.5 stage of development, owing to defective neurogenesis manifested by extensive neuronal apoptosis (12). Moreover, X4 deficiency in primary mouse cells results in the incapacity to support V(D)J recombination (12). To reverse these defects, we generated a transgenic mouse line expressing mouse X4 and crossed it onto the X4 KO background. To avoid the drawbacks (low efficiency, multiple transgenic concatemers, overexpression, or silencing) associated with classical transgenesis, we used lentiviral gene delivery to one-cell embryos (35, 36).

The lentiviral vector used to produce X4 transgenic mice (pTRIP-X4; Fig. 1 A) has the following characteristics: (a) the human ubiquitin C (UbiC) promoter as internal promoter to drive the transgene expression; (b) a LoxP site into the 5′ U3 of 3′LTR, as the duplication of the 3′LTR upon provirus integration results in the mouse X4 transgene being flanked by two LoxP sites (Boxed transgene; Fig. 1 B); and (c) the mouse X4 cDNA is cloned in fusion with a tandem affinity purification (TAP) tag, followed by an ires sequence and the GFP reporter gene. Among various promoters tested (PGK and EF1α), the UbiC proved to have the most pleiotropic specificity, including the hematopoietic system, and a high expression in the brain (unpublished data) (37), which is a prerequisite for the complementation of the embryonic lethality in our model. Using this approach, we obtained 83% transgenic chimeras harboring 1–6 integrated proviruses, as determined by Southern blot and PCR analysis (unpublished data). We selected one chimera with a single integration to derive the X4 transgenic (X4T) line.

Southern blot analysis with probe A (Fig. 1, B and C) revealed a 764-bp EcoNI–AvaII band in X4T-positive and control littermate X4T-negative mice (all on a wild-type background) revealed by anti-X4 antibody. The lentiviral vector used to produce X4 transgenic mice (pTRIP-X4; Fig. 1 A) has the following characteristics: (a) the human ubiquitin C (UbiC) promoter as internal promoter to drive the transgene expression; (b) a LoxP site into the 5′ U3 of 3′LTR, as the duplication of the 3′LTR upon provirus integration results in the mouse X4 transgene being flanked by two LoxP sites (Boxed transgene; Fig. 1 B); and (c) the mouse X4 cDNA is cloned in fusion with a tandem affinity purification (TAP) tag, followed by an ires sequence and the GFP reporter gene. Among various promoters tested (PGK and EF1α), the UbiC proved to have the most pleiotropic specificity, including the hematopoietic system, and a high expression in the brain (unpublished data) (37), which is a prerequisite for the complementation of the embryonic lethality in our model. Using this approach, we obtained 83% transgenic chimeras harboring 1–6 integrated proviruses, as determined by Southern blot and PCR analysis (unpublished data). We selected one chimera with a single integration to derive the X4 transgenic (X4T) line.

Southern blot analysis with probe A (Fig. 1, B and C) revealed a 764-bp EcoNI–AvaII band common to all positive integrations, and an equimolar, unique, integration-specific EcoNI–AvaII–digested DNA from 3′UTR-positive and control littermate 3′UTR-negative mice was hybridized with the 5′ flanking probe A, the internal probe B, and the 3′ flanking probe C as indicated in A. Refer to B for expected sizes of bands. (D) Analysis of X4T expression in transgenic mice. Western blot analysis of X4T transgenic (X4T) and endogenous X4 (bottom) expression in purified splenic mature B cells and thymocytes of X4T mice and control X4T-negative mice (all on a wild-type background) revealed by anti-X4 antibody.

---

**Figure 1.** Creation of X4T transgenic mice. (A) Schematic representation of the pTRIP-X4 lentiviral vector. Restriction sites: E, EcoNI; A, AvaiII. Filled circle, central DNA flap; filled box, X4 Orf, UbiC, human Ubiquitin C promoter. (B) Schematic representation of pTRIP-X4 provirus integrated in the genome of the X4T transgenic mouse line selected for this study. *a, b, c*, the positions of these sites are specific to the integration site. (C) Southern blot analysis of tail DNA shows a single integration of the transgene in the genome of X4T mice. EcoNI–AvaII–digested DNA from X4T-positive and control littermate X4T-negative mice was hybridized with the 5′ flanking probe A, the internal probe B, and the 3′ flanking probe C as indicated in A. Refer to B for expected sizes of bands. (D) Analysis of X4T expression in transgenic mice. Western blot analysis of X4T (top) and endogenous X4 (bottom) expression in purified splenic mature B cells and thymocytes of X4T mice and control X4T-negative mice (all on a wild-type background) revealed by anti-X4 antibody.
X4T reverts the embryonic lethality and reconstitutes B and T cell development in X4-deficient mice

X4T was introduced in the X4 KO background by crosses to derive X4T X4−/− mice, which were born at Mendelian frequency, thus demonstrating the reversal of X4−/− mice embryonic lethality. X4−/− mice succumb to massive apoptosis of postmitotic neuron during development (12). This is characterized by a severe acellularity in the mantle layer of the brain, particularly the cortical plate (CP; Fig. 2, A and B), with the presence of many pyknotic nuclei (Fig. 2 C). In contrast, brain tissue sections of X4T X4−/− mice (Fig. 2, D–F) were indistinguishable from that of control X4+/− mice (Fig. 2, G–I), indicating that expression of X4T in the brain had, indeed, complemented the neuronal apoptosis. FACS analyses of BM, spleen, blood, and thymus, demonstrate the complete immune system recovery in X4T X4−/− mice compared with X4T-negative (WT) littermate mice (Fig. S1, A and B [B cells] and C and D [T cells], available at http://www.jem.org/cgi/content/full/jem.20070255/DC1). Because the phenotypes of B and T cells of 8–12-wk-old control littermates X4+/+ and X4+/− mice were not different (as described by Gao et al. [reference 12]), we associated these mice in the WT (X4T-negative) group. The analysis of B cell subpopulations showed that the proportions of transitional T1 (IgM+/CD21−/CD23−), T2 (IgM+/CD21+/CD23+), marginal zone (MZ; IgM−/CD21+/CD23−), and follicular mature (IgM+/CD21low/CD23+) B cells are not different among the three groups of mice (unpublished data). The serum Ig levels (Fig. S1 G) in X4T X4−/− and control mice were not statistically different, indicating that X4T expression allows B cells to develop into mature IgM-secreting cells and to secrete Ig of switched isotypes, like IgG1, IgG2b, and IgG3 and IgA. Altogether, these results demonstrate that X4T expression reverts the embryonic lethality and the B and T cell development defect in X4−/− mice.

Conditional X4 deletion in mature B cells

To analyze the role of X4 during CSR, we crossed X4T X4−/− mice with CD21-Cre transgenic mice in which the Cre recombinase expression is driven by the CD21 promoter, specifically in mature B cells (38), to create ΔX4T X4−/−, which will be called ΔX4T from this point forward and will always be compared with Cre-negative X4T X4−/−, hereafter named X4T. PCR assay using primers flanking the X4T integration site revealed a ΔX4T-specific PCR mainly in CD43-negative purified splenic B cells and, to a much lesser extent, in total BM, but not in thymus or in DNA from Cre-negative animals (Fig. 3, A and B). Quantitative Southern blot analysis further established that X4T deletion was almost complete in isolated mature splenic B cells from mice expressing Cre recombinase, as demonstrated by the disappearance of the 5.7-kb EcoNI–NdeI X4T-specific band and the concomitant appearance of a 2.3-kb ΔX4T-specific band in a mean proportion of 89% compared with TgWT allele (Fig. 3 C, lanes 7–9). No deletion was observed in liver (Fig. 3 C, lanes 3 and 4), thymus (lanes 11 and 12), or in B cells in the absence of Cre (lanes 5 and 6). These results demonstrate a specific deletion of X4T in mature B cells in ΔX4T mice.

CSR is reduced in conditional X4−/− mice in vivo

To explore the role of X4 in CSR, we quantified the basal serum Ig levels of different isotypes by ELISA in 8–12-wk-old
ΔX4T mice. IgM concentration was not affected (Fig. 4), indicating that X4T deletion in mature B cells does not modify their ability to undergo IgM secretion. In contrast, ΔX4T mice had lower levels of IgG1, IgG2b, and IgG3 (Fig. 4), the difference being statistically significant for IgG2b and IgG3 isotypes. Altogether, the titers were 76, 60, and 41% that of control mice, respectively. No difference in IgA secretion was noted in ΔX4T mice. These results demonstrate a CSR defect in ΔX4T mice in vivo.

CSR is reduced in ΔX4T mice in vitro
Given the specific CD21-Cre–mediated deletion in mature B cells, the CSR defect in ΔX4T mice is probably entirely caused by an intrinsic inability of B cells to undergo CSR. To verify this hypothesis, we induced CSR to different isotypes in vitro by stimulating purified splenic CD43-negative mature B cells from ΔX4T mice with various polyclonal B cell activators. Surface Ig expression on B cells was analyzed by FACS after 4 d of stimulation, and Ig secretion was quantified in day 5 culture supernatants. The frequency of switched mature B cells after 4 d activation was reduced in ΔX4T mice for all the isotypes analyzed (Fig. 5 A). The difference between ΔX4T mice and control mice was statistically significant for IgG1 (P = 0.001) and for IgG2b and IgG3 (P = 0.05). The decrease in cell surface Ig expression on B cells from ΔX4T mice was accompanied by a reduction of the respective Ig secretion in day 5 culture supernatants (Fig. 5 B). We noted a decrease in IgG1 (65% decrease), IgG2b (35%), IgG3 (63%), IgG2a (66%), and IgE (49%) secretion in cultures from X4-deficient B cells, without any decrease in IgM secretion (Fig. 5 B). We conclude that CSR is impaired in ΔX4T mice because of a B cell intrinsic defect.

X4 deficiency does not alter B cell proliferation in vitro
Because the ability to undergo CSR is linked to B cell proliferation (39), we analyzed the consequence of X4 deletion on B cell proliferation in vitro, first through CFSE labeling coupled

![Figure 3. Conditional X4 deletion in mature B cells.](image)

**Figure 3.** Conditional X4 deletion in mature B cells. (A) Schematic representation of the X4T locus before (X4T) and after (ΔX4T) Cre recombination and of a WT allele. Restriction sites: E, EcoNI; N, NdeI. (B) Analysis of X4T deletion by PCR using primers 1 and 2 located in A. Genomic DNA from total BM, purified splenic mature B cells, and thymocytes from X4T X4−/− mice expressing Cre (+) or not (−) were used in the PCR reaction. ΔX4T and WT fragments are indicated. Because of its large size, the X4T fragment is not detected in these PCR conditions. GAPDH-specific PCR was used as loading control. (C) Southern blot analysis of X4T deletion. DNA was prepared from liver, thymus, and from purified splenic mature B cells, digested with EcoNI–NdeI, and hybridized with chromosome 16 integration site-specific probe D (refer to A for expected sizes of bands). Quantification of deletion is indicated below lanes 7, 8, and 9 as the percentage of the amount of ΔX4T compared with WT allele.

![Figure 4. Ig production is impaired in conditional X4 KO mice.](image)

**Figure 4.** Ig production is impaired in conditional X4 KO mice. Sera from ΔX4T and control X4T mice were collected and total IgM, IgG1, IgG2b, IgG3, and IgA were determined by ELISA (microgram/milliliter). The results of statistical tests are indicated; * indicates a statistically significant difference (P < 0.05, two-tailed Mann-Whitney test).
with Ig isotype determination (Fig. 5, C–G). The frequency of cells expressing various Ig isotypes was determined by flow cytometry after 4 d of stimulation in the overall B220+ B cell population, as well as among the various subsets of proliferative B cells according to CFSE intensity. The overall proliferative capacity of B cells was not altered by the X4 deletion in culture stimulated with LPS/IL-4 and LPS (Fig. 5 D) or with anti-CD40/IL-4/IFNγ and anti-CD40/IL-4/TGFβ (Fig. 5 F), even in cells that underwent several cycles of cell division. Most importantly, the decrease in CSR to IgG1 and IgG3 (Fig. 5, E and G), IgG2a, IgG2b, and IgA (Fig. 5 G) was not restricted to the cells that had proliferated less. Interestingly, the CSR defect, indeed, appears to increase with the extent of proliferation (see Discussion; Fig. 5, E and G). Moreover, cell survival, determined by propidium iodide staining on day 4, was not reduced in ΔX4T versus control mice (P = 0.86 for LPS stimulation; P = 0.45 for LPS/IL-4 stimulation, two-tailed Mann-Whitney test).

Altogether, these results demonstrate a diminution in CSR in B cells deficient for X4 both in vitro and in vivo, which is not attributable to a reduced capacity of clonal expansion or a decrease in cell survival.

**X4 deficiency reduces CSR at the level of DNA recombination**

The function of X4 in ligation of DNA DSB suggests that the observed defect in CSR could intervene at the level of DNA recombination, i.e., after induction of AID expression and germline transcription of the CH genes targeted for recombination, i.e., after induction of AID expression and germline transcription of CH loci targeted for ligation of DNA DSB produced in CSR after the induc-....

**Why is the defect of CSR in ΔX4T B cells partial?**

The CSR defect observed in the absence of X4 both in vitro and in vivo is partial. As shown in Fig. 3 C, X4T deletion efficiency is almost complete and so likely does not account for the partial nature of the CSR defect in ΔX4T mice. Given the structure of the X4T transgene, with LoxP sites flanking the transcriptional unit upon virus integration (Fig. 7 A), the partial CSR defect observed in ΔX4T B cells could reflect the persistence of X4T expression from the Cre-excised X4T cassette in mature B cells. To explore this possibility, we performed a Southern blot analysis using a probe specific for the third exon of the XRCC4 gene (Fig. 7 A, probe E), which is deleted in X4 KO mice (12). The 2.8-kb Ndel band revealed by probe E and specific for the X4 WT allele (Fig. 7 B, lane 13) was absent in all samples from mice deficient for endogenous X4, as expected (X4T and ΔX4T mice; Fig. 7 B, lanes 1 to 12). In contrast, hybridization with probe E revealed the integrated X4T transgene as a 5.7-kb EcoNI–Ndel band in Cre-negative, X4T mice (Fig. 7 B, lanes 1, 2, 5, 6, and 10), as well as in liver and thymus from ΔX4T mice (lanes 3, 4, 11, and 12), but not in purified mature B cells from ΔX4T mice (lanes 7–9), where it is replaced by a 4.7-kb band. The size of this band was compatible with that of the Cre-excised X4T cassette as a circular episome (Fig. 7 A, episomal X4T and eX4T).

**Table I. Increased microhomology at Sμ-Sγ1 junctions in B cells deficient for X4**

| Sμ-Sγ1 junctions | Perfectly matched homology | Total n° of S junctions |
|------------------|---------------------------|------------------------|
| X4T              | 30 (60%)                  | 1–3 bp                 | 4–6 bp                  | 7–9 bp                  | ≥10 bp                  | 50 |
| ΔX4T             | 23 (46%)                  | 17 (34%)               | 2 (4%)                  | 1 (2%)                  | 0 (0%)                  | 50 |

Purified splenic mature B cells from ΔX4T and X4T mice were stimulated for 4 d with LPS and IL-4, and then Sμ-Sγ1 junctions were amplified by PCR and sequenced. Microhomology was determined by identifying the longest region of perfect donor/acceptor identity at the switch junction. See Fig. S2 for sequence data, available at http://www.jem.org/cgi/content/full/jem.20070255/DC1.
Figure 5. CSR defect in X4-deficient B lymphocytes in vitro. Surface expression and secretion of switched isotypes. Purified splenic mature B cells from ΔX4T and control X4T mice were labeled with CFSE and stimulated for 4 or 5 d with various polyclonal B cell activators for switching. (A) Percentage of total B cells expressing indicated isotypes of Ig, as determined by flow cytometry analysis, after 4 d of in vitro stimulation. (B) Secreted Ig (nanogram/milliliter) was analyzed in supernatants from splenic B cells cultures after 5-d in vitro stimulation. IgA was undetectable in supernatants. For A and B, the results of statistical tests are indicated; * indicates a statistically significant difference (P < 0.05, two-tailed Mann-Whitney test). (C–G) Analysis of CSR in the various subsets of proliferative B cells according to CFSE intensity. (C) Plots show IgG1 (top) and IgG3 (bottom) staining together with CFSE, on viable (PI−) lymphoid cells. The percentages of switched cells are given.

1722
The X4T episome was further detected by PCR (Fig. 7 A, primers 1 and 2), specifically in purified splenic mature B cells from mice expressing Cre recombinase, but not in thymus or liver from these mice (Fig. 7 C, left). The reduced intensity of the eX4T PCR product in B cells after 4-d activation (Fig. 7 C, right) suggests that although this episome is not degraded upon Cre-mediated excision, it is diluted out with cellular proliferation, which is a situation reminiscent of the TCR-α rearrangement excision circles in thymocytes (40). These results were confirmed by a real-time quantitative RT-PCR using a probe specific for the second and third exon of the XRCC4 gene, which demonstrates that, whereas the level of X4 transcripts is comparable in purified splenic mature B cells from X4T and ΔX4T mice (Fig. 7 D, d0), the amount of X4 transcripts sharply decreases in B cells from ΔX4T mice after 4-d activation in vitro (Fig. 7 D, d4).

Together, these results indicate that whereas the X4T transgene is almost completely deleted from chromosome in mature B cells expressing Cre, the X4T transcriptional unit is not degraded and still expressed in early deleted cells. Even though this expression is lost upon episome dilution that occurs during B cell proliferation, it could mask or attenuate the CSR defect and a differential resolution of CSR junctions in B cells from ΔX4T mice.

DISCUSSION

Although mutant mice have implicated the NHEJ pathway in CSR (27, 28, 30), the direct demonstration of the participation of X4 in this process was lacking. This question cannot be addressed easily in X4-deficient mice because of their embryonic lethality and V(D)J recombination defect (12). To overcome this limitation, we developed a lentiviral transgenic mouse line expressing one copy of the floxed mouse X4 transgene (named X4T), and crossed it onto a X4-deficient background. The X4T transgene reverts embryonic lethality of X4-deficient mice and allows for the normal development of a mature immune system.

The transgenic line thus obtained is amenable to conditional inactivation through Cre-mediated excision of the LoxP-flanked cDNA transgene.

This experimental scheme presents several advantages over the classical conditional KO strategy by introducing LoxP sites in the genome. First, the lentiviral transgenesis is very efficient and much less effort/time demanding than homologous recombination in embryonic stem cells. It can be used in conjunction with all the already existing KO mice that were not primarily designed for conditional KO (which was the case for the X4 KO mice we used in this study). Second, the same strategy can also be applied to the ever-growing list of mutant mice obtained either through ENU (N-ethyl-N-nitrosourea) or insertional mutagenesis. Third, the use of TAP-Tag fused to cDNAs makes it possible to perform ex vivo proteomic studies from these transgenic animals. Lastly, the introduction of an iresGFP cassette should allow tracking of cells that have undergone Cre-mediated excision of the transgene, although, in our case, the ires sequence used in the X4T transgenic mice proved to be nonfunctional in vivo. One limitation of this strategy comes from the location of the LoxP site in the 3′LTR of the lentiviral vector. The Cre-mediated, excised episome is not degraded, and it still expresses the transgene in cells that carry it. It is ultimately lost by dilution upon cell proliferation. Although this may not represent a problem for rapidly dividing cells, it certainly constitutes a major drawback for studies in nonproliferating tissues (such as postmitotic neurons), and it may result in a hypomorphic CSR phenotype in ΔX4T mice. The repositioning of LoxP sites between the UbiC promoter and the cDNA in the lentiviral vector should eliminate this problem.

To study the role of X4 in CSR, we crossed X4T X4−/− mice to CD21–Cre transgenic mice (38), which lead to an almost complete deletion of the floxed X4T from the genome, specifically in mature B cells from the resulting ΔX4T mice. These mice demonstrate reduced CSR in vivo and in vitro, thus confirming an intrinsic failure of X4-deficient B cells to undergo CSR. Several studies have linked CSR to the capacity of B cells to proliferate (39, 41, 42). The proliferative capacity of B cells from ΔX4T mice was not affected, arguing for the role of X4 during the CSR rearrangement process. The inverse correlation between the proliferation and CSR levels in B cells from ΔX4T mice, owing to the progressive loss of the eX4T episome (see below), further strengthens this conclusion.

CSR is strictly dependent on AID enzyme, and on the production of sterile germline transcripts (GTs) from the CH genes that are to be recombined, which may provide the accessibility of DNA to the recombination machinery. CSR leads to the production of post-switch circle transcripts (15). Induction of AID and expression of μGT and γ1GT transcripts are normal in X4-deficient B cells after stimulation division, the decrease of CSR to IgG1, IgG2a, IgG2b, IgG3, and IgA, in B cells from ΔX4T compared with X4T mice is represented as a percentage of CSR defect.

Figure 6. Ig γ1 circle transcript production is impaired in X4-deficient B cells. Purified splenic mature B cells from ΔX4T and X4T mice were stimulated with LPS and IL-4 for 4 d, and μGT, γ1GT, γ1CT, and AID transcripts were quantified by real-time RT-PCR. Each point represents the level for the indicated transcript in ΔX4T mice (which has been normalized to CD19 transcripts) relative to X4T mice analyzed in the same experiment.

(D–F) Percentages of total (D and F) and IgG1-switched (E, top) or IgG3-switched (E, bottom) B cells that have undergone the indicated numbers of cell division, for ΔX4T [white] and X4T [gray] mice. (G) In each cell
in vitro, whereas the amount of CSR as measured by circular γ1 transcripts is reduced, indicating that X4 deficiency impairs the ligation of broken S regions during CSR.

To explore the possibility that an alternative, X4-independent pathway could account for the partial resolution in CSR junctions in ∆X4T mice, we analyzed Sμ-Sγ1 junction sequences in purified mature splenic B cells after stimulation with LPS and IL-4, and found a slight increase in the use of microhomologies in ∆X4T B cells. Although this increase concerns only short microhomologies and is not statistically significant, these results are reminiscent of the CSR junctions from a DNA ligase IV−deficient patient (34) and from ATM−deficient mice (22) and of the existence of alternative end-joining mechanisms using microhomologies, in V(D)J junctions in Ku86−deficient mice, or in plasmid assays in DNA ligase IV or XRCC4−deficient systems (43–47). Notably, Verkaik et al. developed an assay in which a DNA substrate is linearized in such a way that joining on a particular microhomology creates a novel restriction enzyme site; in this assay, XRCC4−deficient XR−1 cells and DNA ligase IV−deficient N114 or 180BR cells showed an increased microhomology use (44).

A residual expression of X4 transcripts after Cre deletion could also participate in the partial CSR defect in this setting. Indeed, the Cre recombination process generates an episomal DNA that carries the X4T transcriptional unit (eX4T), which persists in nontdividing mature B cells, can be transcribed, and is diluted out upon cell proliferation in vitro, leading to the concomitant decrease of X4 transcription. Moreover, the CSR defect increases in cells that have undergone several rounds of cell division as assessed by CFSE labeling coupled to Ig surface expression analysis (Fig. 5, E and G); as an example, B lymphocytes that have undergone zero versus six cycles of cell division show 28 and 57% CSR defect to IgG3, respectively. This was true for all analyzed isotypes. These observations support the idea that the CSR process is efficient to some extent in ∆X4T B cells ongoing few divisions because of the persistence of eX4T, but becomes less and less efficient as cells go through several cycles of proliferation and lose the episome. We propose that the partial defect of CSR observed after 4 d of stimulation in vitro is the result of the sum of these events. This interpretation implies that we may underestimate the role of X4 in CSR in our experimental system.

A requirement for the NHEJ factors Ku70 and Ku80 during CSR has been established in complemented KO mice harboring monoclonal B cell population (20, 27, 28). However, these factors also carry NHEJ−independent functions in DNA repair, probably through their interaction with ATM (48).
In contrast, X4 is not known to be involved in pathways other than NHEJ. The experimental system we describe in this study provides the first evidences for a role of X4 in CSR. X4 belongs probably DNA ligase IV and Cernunnos as well, play a role in CSR by promoting the final joining of the two broken end regions, in agreement with the results from Pan-Hammars-ström in patient with hypomorphic mutations in DNA ligase IV gene (34). This is also in accord with our observation that some Cernunnos-deficient patients present a hyper-IgM syndrome, a hallmark of a CSR defect in humans (3). The development of DNA ligase IV and Cernunnos conditional KO mice should definitely accredit this conclusion. Our study also highlights the DNA ligase IV and Cernunnos conditional KO mice should a hallmark of a CSR defect in humans (3). The development of DNA ligase IV and Cernunnos conditional KO mice should probably DNA ligase IV and Cernunnos as well, play a role in CSR through NHEJ. X4, and probably DNA ligase IV and Cernunnos as well, play a role in CSR by promoting the final joining of the two broken end regions, in agreement with the results from Pan-Hammars-ström in patient with hypomorphic mutations in DNA ligase IV gene (34). This is also in accord with our observation that some Cernunnos-deficient patients present a hyper-IgM syndrome, a hallmark of a CSR defect in humans (3).

**MATERIALS AND METHODS**

**DNA constructs.** The self-inactivating lentiviral vector pTRIP-Ubi-X4-TAP-iresGFP-∆U3-LoxP (Fig. 1 A) used to produce transgenic mice was constructed as follows: the lentiviral pTRIP-Ubi-GFP-U3 was obtained by substituting the EFla promoter for the human ubiquitin C promoter from pUbi-JunB (provided by P. Angel, Deutshces Krebsforschungszenrum, Heidelberg, Germany [reference 37]) in M1dI and BamHI sites of pTRIP-EFla-GFP-U3 (49). A LoxP site (AAACCTTGTATAATGGATCTAGCAAGATTTAT) was inserted in the lentiviral ∆U3-R–U5 3'LTR fragment in PL plasmid (provided by P. Chasseau, Institut Pasteur, Paris, France). This ∆U3-R–U5 LoxP fragment was used to replace the U3/R/U5 3'LTR in pTRIP-Ubi-GFP-U3, producing pTRIP-Ubi-GFP-∆U3-LoxP. The GFP fragment was replaced by a TAP-iresGFP cassette to obtain pTRIP-Ubi-TAP-iresGFP-∆U3-LoxP. The sequence consists in the calmodulin-binding protein (50). Finally, the pTRIP-Ubi-X4-TAP-iresGFP-∆U3-LoxP lentivector was constructed by introducing the mouse ORF X4 ORF infarne with the TAP tag. We will refer to this vector as pTRIP-X4.

**Virus production and titration.** Lentiviral particles were produced by transfection of 293T cells, as previously described (49).

**Mice.** A volume of 10 μl of virus at 5 × 10⁶ IU/ml was injected into the perrivelline space of one-cell stage B6D2F1 mouse embryos. Embryos were reimplanted into pseudopregnant females. A single-copy X4 founder line was selected for further analysis. Conditional X4 KO mice were obtained by breeding the X4 transgenic line to X4 KO mice (provided by F. Alt, Harvard Medical School, Boston, MA) (12) and CD21-Cre transgenic mice (provided by K. Rajewsky, Harvard Medical School, Boston, MA) (38). Pregney were screened by PCR on tail DNA. Mice were bred and maintained under specific pathogen-free conditions. All mice used in this study were 8–12 wk old. Mouse experiments were with the approval of institutional committee from the french ministry of agriculture.

**Analysis of the number of proviral integrations by Southern blotting.** The number of proviral integrations was analyzed by Southern blot (Fig. 1) on AvaiI- and EcoNI-digested tail DNA, as previously described (49), using the following vector probes: 1,027-bp 5' flanking probe A (49), 638-bp internal GFP probe B, and 253-bp 3' flanking probe C (Fig. 1 B). The signal was quantified using ImageQuant software.

**Analysis of X4T deletion by Southern blotting.** DNA from liver, thymus, and purified splenic mature B cells was digested with EcoNI and NdeI. Southern blots were hybridized with the 795-bp probe D (Fig. 3 A) and the 327-bp probe E (Fig. 7 A) and quantified using ImageQuant software.

**Determination of provirus site integration by inverse PCR.** 1 μg tail DNA from a X4T transgenic mouse was digested with MboI and ligated with T4 DNA ligase (Invitrogen), and inverse PCR was performed with Platinum Taq DNA Polymerase High Fidelity (Invitrogen) in two-round reactions. The first round used provirus-specific oligonucleotide primers (5'-GACTCGGTCTAAGGC-3' and 5'-GGAGAGGCTCTCCCTTGTTTCT-3'). Amplification conditions were 4 cycles at 94°C (30 s), 65°C (30 s), and 68°C (2 min); 4 cycles at 94°C (30 s), 63°C (30 s), 68°C (2 min); and 27 cycles at 94°C (30 s), 60°C (30 s), 68°C (30 s + 10 s/cycle). 5 μl of the first PCR product was reamplified with an internal set of primers (5'-GGG-GGAGAATTAGATCCG-3' and 5'-CTTCTCAAGTCCCTGTTCGG-3'), with 4 cycles at 94°C (30 s), 62°C (30 s), 68°C (2 min); 4 cycles at 94°C (30 s), 60°C (30 s), 68°C (2 min); and 27 cycles at 94°C (30 s), 57°C (30 s), 68°C (30 s + 10 s/cycle). The resulting 2-kb PCR fragment was gel purified, sequenced, and blasted against the mouse genome.

**Analysis of X4T deletion and detection of episomal X4T by PCR.** X4T deletion was analyzed by PCR on DNA from BM, thymus, and purified splenic mature B cells using primers designed in the genomic sequence flanking the X4T integration site (K16F, K16R). GAPDH-specific PCR was used as loading control. The Cre-excised X4T episome was detected by PCR using primers 1 and 2 depicted in Fig. 7 A (5'F, 5'R). Artemis- and GAPDH-specific PCRs were used as loading controls. The PCR assay was performed on 20 ng of DNA (and one-third serial dilutions of DNA when indicated). The primers used were as follows: K16-F (5'-GGCTGCTTGCG-CTGTTCTTAGT-3'), K16-R (5'-AAGCATGCGAGACTCTCAT-3'), GAPDH-F (5'-AGATGTAGCAGAAAGG-3'), and GAPDH-R (5'-ATGTTATCAAGAGATGGG-3'); 3'F1 (5'-GCTGCGTTAGACACAAGAG-3') and 5'R1 (5'-CGAGAGAGCTCTCCTGTTCG-3'); Artemis-K5 (5'-TCCATGACCTTATCCACAGTGAAG-3') and K5.4 (5'-TCTCTCCTCTCCCTCCCCACATAG-3').

**Analysis of transgene expression by Western blotting.** Whole-cell extracts were prepared from thymus and spleen according to standard protocols. X4T and endogenous X4 were detected with rabbit polyclonal anti-XRCC4 antibody (AHP387; Serotec), followed by HRP-goat anti-rabbit antibody (GE Healthcare).

**Histological analysis of mouse brain sections.** Embryos were fixed in 4% paraformaldehyde, embedded in 15% sucrose and 7.5% gelatine in PBS, serially sectioned (16 μm), and stained with hematoxylin and eosin, as previously described (12).

**Flow cytometry analysis of lymphocyte populations and Ig CSR.** Cell phenotype was performed on blood, thymic, splenic, and BM lymphoid populations by four-color fluorescence analysis according to standard protocols. The following antibodies were used: FITC, PE, or APC–anti–mouse B220, CD21, CD23, CD3, CD8, and CD4 (all from BD Biosciences); Cy5 anti–mouse IgM (Jackson Immunoresearch Laboratories). For analysis of CSR, cells were stained with PE anti–mouse B220 (BD Biosciences); biotin anti–mouse IgG1, IgG2a, IgG2b, IgG3, IgA, and IgE (Southern Biotechnology Associates); and APC-streptavidin (BD Biosciences). Cells were analyzed using a FACSCalibur immediately after incubation with 5 μg/ml propidium iodide to exclude dead cells.

**Purification and activation of splenic mature B cells in vitro.** Mature B cells were purified from spleen and labeled with CFDA-SE, as previously described (20), and stimulated for 4 or 5 d with 25 μg/ml LPS from Escherichia coli (Sigma-Aldrich), 20 ng/ml IL-4 (R&D Systems), and 0.5 μg/ml anti–mouse CD40 (BD Biosciences), 1 ng/ml human TGFβ1 (R&D Systems), 0.5 μg/ml recombinant mouse IFNγ (PeproTech France) for 4 and 5 d, in the following combinations: LPS for IgG2b and IgG3 switching, LPS/IL-4 for IgG1 and IgE switching, anti–mouse CD40/IL-4/IFNγ for IgG2a switching, and anti–mouse CD40/IL-4/TGFβ for IgA switching.
Antibody detection by ELISA. Total IgA, IgG1, IgG2a, IgG2b, IgG3, IgE, or IgM levels were measured in serum from 8–12-wk-old mice, and in supernatants after 4 d of stimulation, as previously described (22). The wells were developed with Fast OPD substrate (Sigma-Aldrich). Absorbance was measured at 490 nm. Levels of Ig were determined by comparison with a standard curve using purified IgA, IgG1, IgG2a, IgG2b, IgG3, IgE (all from Southern Biotechnology Associates), and IgM (Sigma-Aldrich).

Sequencing of μ/γ1 switch recombination junctions. Genomic DNA was prepared from sorted IgG1+ B cells after 4 d of stimulation with LPS and IL-4, and Sγ1/γ1 switch junctions were amplified by PCR as previously described (20). PCR products were cloned using pGEM-T vector (Promega) and sequenced using SP6 and T7 universal primers. Sequence analysis was performed using Blast2 sequences in comparison with mouse Sγ1 (MUSIGCD07) and Sγ1 (MUSIGHANB) regions.

Quantitative real-time RT-PCR analysis of CSR transcripts. cDNA was prepared from total RNA extracted from B cells after 4 d of stimulation with LPS and IL-4, and Sγ1/γ1Cγ1 switch junctions were amplified by PCR as previously described (20). PCR products were cloned using pGEM-T vector (Promega) and sequenced using SP6 and T7 universal primers. Sequence analysis was performed using Blast2 sequences in comparison with mouse Sγ1 switch recombination junctions. Primers used for CD19 transcripts quantification were CD19F′ (5′-CCATCGAGGACGTGGA-3′) and CD19R (5′-TCCAATCCA-CCAGTTCTCACAAG-3′) (52).

Quantitative real-time RT-PCR analysis of X4 transcripts. Quantitative real-time PCR was performed on 20 ng cDNA using Taqman Universal Mastermix (Applied Biosystems) and Assays-on-Demand reaction (Applied Biosystems) including forward and reverse primers and the 6-carboxy-fluorescein (FAM)–labeled probe for the target gene (assay for mouse X4 exons 2–3 was no. Mm01283065_m1; for 18S, it was Hs99999901_s1). Conditions for PCR amplification and detection were: 50°C (2 min), 95°C (10 min), and 40 cycles at 95°C (15 s), 60°C (60 s). Each sample was amplified in quadruplicate, mRNA levels were calculated with the sequence detector SDS2.1 software (Applied Biosystems), using the comparative cycle threshold method, and normalized to the endogenous control 18S.

Online supplemental material. Fig. S1 shows B and T cell development in X4−/− mice complemented with X4T. FACs analysis and serum Ig level determination show the complete immune recovery in X4T X4−/− mice compared with X4T-negative (WT) mice. Fig. S2 illustrates the Sγ1-γ1 junction sequence data (25 bp upstream and downstream of each junction) in X4-deficient B cells. Sequence analysis was performed using Blast2 sequences in comparison with mouse Sγ1 (MUSIGCD07) and Sγ1 (MUSIGHANB) regions. The online version of this article is available at http://www.jem.org/cgi/content/full/jem.20070255/DC1.

We thank Dr. F. Alt for X4 KO mice and Dr. K. Rajewsky for providing the CD21-Cre transgenic mice; A. Rossard and M. Gaillard for excellent animal care; P. Souque for technical help in virus production; and B Reina-San-Martin for critical reading of the manuscript.

This work was supported by grants from l’Institut National de la Santé et de la Recherche Médicale (INSERM), the Ligue Nationale contre le Cancer (Equipe labellisée LA LIGUE 2005), the Commissariat à l’Energie Atomique (LRC-DGA N400V), and the Institut National de Cancer/Cancéropôle Ile de France. P. Souslas-Sprauel was supported by INSERM, Electricité de France (EDF) and the Fondation Singer Polignac.

The authors have no conflicting financial interests.

Submitted: 5 February 2007
Accepted: 8 June 2007

REFERENCES
1. de Villartay, J.P., A. Fischer, and A. Durandy. 2003. The mechanisms of immune diversification and their disorders. Nat. Rev. Immunol. 3:962–972.
2. Revy, P., D. Buck, F. le Deist, and J.P. de Villartay. 2005. The repair of DNA damages/modifications during the maturation of the immune system: lessons from human primary immunodeficiency disorders and animal models. Adv. Immunol. 87:237–295.
3. Buck, D., L. Malivert, R. de Chasseval, A. Barraud, M.C. Fondaneche, O. Sanal, A. Plebani, J.L. Stephen, M. Hufnagel, F. le Deist, et al. 2006. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell. 124:287–299.
4. Callebaut, I., L. Malivert, A. Fischer, J.P. Morrow, P. Revy, and J.P. de Villartay. 2006. Cernunnos interacts with the XRCC4 x DNA-ligase IV complex and is homologous to the yeast nonhomologous end-joining factor Nej1. J. Biol. Chem. 281:13857–13860.
5. Ahnouog, P., P. Smith, and S.P. Jackson. 2006. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell. 124:301–313.
6. Moshou, D., I. Callebaut, R. de Chasseval, B. Corneo, M. Cavazzana-Calvo, F. Le Deist, I. Tezcan, O. Sanal, Y. Bertrand, N. Philippe, et al. 2001. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 105:177–186.
7. Barnes, D.E., G. Stamp, I. Rosewell, A. Denzel, and T. Lindahl. 1998. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr. Biol. 8:1395–1398.
8. O’Driscoll, M., K.M. Cerioletti, P.M. Girard, Y. Dui, M. Stumnn, B. Kysela, B. Hirsch, A. Gennery, S.E. Palmer, J. Seidel, et al. 2001. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol. Cell. 8:1175–1185.
9. Rooney, S., J. Sekiguchi, C. Zhu, H.L. Cheng, J. Manis, S. Whitlow, J. DeVido, D. Foy, J. Chaudhuri, D. Lombard, and F.W. Alt. 2002. Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Mol. Cell. 10:1379–1390.
10. Frank, K.M., J.M. Sekiguchi, K.J. Seidl, W. Swat, G.A. Rathbun, H.L. Cheng, L. Davidson, L. Kangalo, and F.W. Alt. 1998. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature. 396:173–177.
11. Gao, Y., Y. Sun, K.M. Frank, P. Dikkes, Y. Fujigawa, K.J. Seidl, J.M. Sekiguchi, G.A. Rathbun, W. Swat, J. Wang, et al. 1998. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell. 95:891–902.
12. Bosmu, M.J., and A.M. Carroll. 1991. The SCID mouse mutant: definition, characterization, and potential uses. Annu. Rev. Immunol. 9:323–350.
13. Bassing, C.H., W. Swat, and F.W. Alt. 2002. The mechanism and regulation of chromosomal V(D)J recombination. Cell. 109(Suppl.):S45–S55.
14. Chaudhuri, J., and F.W. Alt. 2004. V(D)J-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat. Rev. Immunol. 4:541–552.
15. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 102:553–563.
16. Revy, P., T. Muto, Y. Levy, F. Grissmann, A. Plebani, O. Sanal, N. Catalan, M. Forreille, R. Dufourcq-Labelouse, A. Gennery, et al. 2000. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 102:565–575.
17. Wuerffel, R.A., J. Du, R.J. Thompson, and A.L. Kenter. 1997. Ig Σ gamma3 DNA-specific double strand breaks are induced in mitogen-activated B cells and are implicated in switch recombination. J. Immunol. 159:4139–4144.
18. Petersen, S., R. Casellas, B. Reina-San-Martin, H.T. Chen, M.J. Difilippantonio, P.C. Wilson, L. Hantsch, A. Celeste, M. Muramatsu, D.R. Pitch, et al. 2001. AID is required to initiate Nbs1/gammaH2AX focus formation and mutations at sites of class switching. Nature. 414:660–665.
20. Reina-San-Martin, B., S. Difilippantonio, L. Hamitouch, R.F. Maslakman, A. Nussenzwieg, and M.C. Nussenzweig. 2003. H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. *J. Exp. Med.* 197:1767–1778.

21. Reina-San-Martin, B., H.T. Chen, A. Nussenzweig, and M.C. Nussenzweig. 2004. ATM is required for efficient recombination between immunoglobulin switch regions. *J. Exp. Med.* 200:1103–1110.

22. Lumsden, J.M., T. McCarty, L.K. Petiniot, R. Shen, C. Barlow, T.A. Wynn, H.C. Morse III, P.J. Gearhart, E.E. Max, and R.J. Hodes. 2004. Immunoglobulin class switch recombination is impaired in Atm-deficient mice. *J. Exp. Med.* 200:1111–1121.

23. Manis, J.P., J.C. Morales, Z. Xia, J.L. Kutok, F.W. Alt, and P.B. Carpenter. 2004. 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. *Nat. Immunol.* 5:481–487.

24. Ward, I.M., B. Reina-San-Martin, A. Olaru, K. Minn, K. Tamada, J.S. Lau, M. Cascallo, L. Chen, A. Nussenzwieg, F. Livak, et al. 2004. 53BP1 is required for class switch recombination. *J. Cell Biol.* 165:459–464.

25. Reina-San-Martin, B., M.C. Nussenzweig, A. Nussenzweig, and S. Difilippantonio. 2005. Genomic instability, endoreduplication, and diminished Ig class-switch recombination in B cells lacking Nbs1. *Proc. Natl. Acad. Sci. USA* 102:1590–1595.

26. Kracker, S., Y. Bergmann, I. Demuth, P.O. Frappart, G. Hildebrand, R. Christune, Z.Q. Wang, K. Sperling, M. Diggweed, and A. Rall. 2005. Nibrin functions in Ig class-switch recombination. *Proc. Natl. Acad. Sci. USA* 102:1584–1589.

27. Manis, J.P., Y. Gu, R. Lansford, E. Sonoda, R. Ferrini, L. Davidson, K. Rajewsky, and F.W. Alt. 1998. Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. *J. Exp. Med.* 187:2081–2089.

28. Casellas, R., A. Nussenzwieg, R. Wuerffel, R. Pelanda, A. Rechlin, H. Suh, X.F. Qin, E. Besmer, A. Kajino, K. Rajewsky, and F.W. Alt. 1999. Ku80 is required for immunoglobulin isotype switching. *EMBO J.* 17:2404–2411.

29. Cook, A.J., L. Oganesian, P. Harunmal, A. Basten, R. Brink, and C.J. Jolly. 2003. Reduced switching in SCID B cells is associated with altered somatic mutation of recombined S regions. *J. Immunol.* 171:6556–6564.

30. Manis, J.P., D. Dudley, L. Kaylor, and F.W. Alt. 2002. IgH class switch recombination to IgG1 in DNA-PKcs-deficient B cells. *Immunity* 16:607–617.

31. Bosma, G.C., J. Kim, T. Urich, D.M. Fath, M.G. Cotticelli, N.R. Ruetsch, M.Z. Radic, and M.J. Bosma. 2002. DNA-dependent protein kinase activity is not required for immunoglobulin class switching. *J. Exp. Med.* 196:1483–1495.

32. Kiefer, K., J. Oshinsky, J. Kim, P.B. Nakajima, G.C. Bosma, and M.J. Bosma. 2007. The catalytic subunit of DNA-protein kinase (DNA-PKcs) is not required for Ig class-switch recombination. *Proc. Natl. Acad. Sci. USA* 104:2843–2848.

33. Rooney, S., F.W. Alt, J. Sekiguchi, and J.P. Manis. 2005. Artemis-independent functions of DNA-dependent protein kinase in Ig heavy chain class switch recombination and development. *Proc. Natl. Acad. Sci. USA* 102:2471–2475.

34. Pan-Hammarström, Q., A.M. Jones, A. Lahdesmaki, W. Zhou, R.A. Gatti, L. Hammarström, A.R. Gennery, and M.R. Ehrenstein. 2005. Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. *J. Exp. Med.* 201:189–194.

35. Lois, C., E.J. Hong, S. Pease, E.J. Brown, and D. Baltimore. 2002. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. *Science* 295:868–872.